Signs and Stages

start the movement — recognize and treat osteoarthritis (oa) early
Understanding the stages of OA and the benefits of early identification and multimodal treatment can evolve your practice and keep your patients active and comfortable.
Dogs may be suffering in silence.
time graphic
time graphic mobile
OA affects 1 in 5 dogs.3
five dogs
OA can occur at any stage in a dog’s life.
The risk factors for canine OA include breed disposition, intense activity, joint injury, joint surgery and obesity2.
Help pet owners understand that OA can occur at any stage in a dog’s life.
dog stage
dog stage mobile
Treat the pain of canine OA from the
earliest diagnosed stages.
  • Control pain sooner rather than later as an important part of canine OA treatment2,4,5
  • Make an NSAID the cornerstone of your multimodal treatment plan
  • Enable effective rehabilitation programs to improve strength and posture, and optimize body weight
  • As a veterinarian, you want to provide the best care for your canine OA patients, but sometimes the worry about long-term risks can delay prescribing the relief they need today6,7
multimodal graph
Galliprant® (grapiprant tablets) is one option that might make veterinarians feel comfortable about treating OA pain early.*
Duncan Lascelles
BSc, BVSc, PhD, MRCVS, CertVA, DSAS(ST), DECVS, DACVS
*Excerpted or adapted from Clinician’s Forum: Expert Views from a Roundtable — Canine Osteoarthritis: Optimizing Diagnosis and Disease Management. September 2017.
Use the COAST staging tool to help diagnose canine OA at its earliest stages.

Galliprant is an NSAID indicated for the control of pain and inflammation associated with osteoarthritis in dogs.

Not for use in humans. For use in dogs only. Keep this and all medications out of reach of children and pets. Store out of reach of dogs and other pets in a secured location in order to prevent accidental ingestion or overdose. Do not use in dogs that have a hypersensitivity to grapiprant. If Galliprant is used long term, appropriate monitoring is recommended. Concomitant use of Galliprant with other anti-inflammatory drugs, such as COX-inhibiting NSAIDs or corticosteroids, should be avoided. Concurrent use with other anti-inflammatory drugs or protein-bound drugs has not been studied. The safe use of Galliprant has not been evaluated in dogs younger than 9 months of age and less than 8 lbs (3.6 kg), dogs used for breeding, pregnant or lactating dogs, or dogs with cardiac disease. The most common adverse reactions were vomiting, diarrhea, decreased appetite, and lethargy. Click here for full prescribing information.